UY25108A1 - Modificación termodinámicamente estable de 1-(4-carbazoliloxi)-3-[2-(2-metoxifenoxi)etilamino]-2-propanol, procedimiento para su preparación y composiciones farmacéuticas que lo contienen. - Google Patents

Modificación termodinámicamente estable de 1-(4-carbazoliloxi)-3-[2-(2-metoxifenoxi)etilamino]-2-propanol, procedimiento para su preparación y composiciones farmacéuticas que lo contienen.

Info

Publication number
UY25108A1
UY25108A1 UY25108A UY25108A UY25108A1 UY 25108 A1 UY25108 A1 UY 25108A1 UY 25108 A UY25108 A UY 25108A UY 25108 A UY25108 A UY 25108A UY 25108 A1 UY25108 A1 UY 25108A1
Authority
UY
Uruguay
Prior art keywords
propanol
procedure
preparation
pharmaceutical compositions
thermodynamically stable
Prior art date
Application number
UY25108A
Other languages
English (en)
Inventor
Peter Beyer
Erhard Reinholz
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Publication of UY25108A1 publication Critical patent/UY25108A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una nueva modificación termodinámicamente estable de 1-(4-carbazoliloxi)-3-(2-(2-metoxifenoxi)etilamino)-2-propanol (carvedilol), sales farmacológicamente aceptables, o formas ópticamente activas de la misma, procedimiento para su preparación, y composiciones farmacéuticas que la contienen. El carvedilol es útil en el tratamiento y/o profilaxis de enfermedades cardíacas.
UY25108A 1997-07-22 1998-07-22 Modificación termodinámicamente estable de 1-(4-carbazoliloxi)-3-[2-(2-metoxifenoxi)etilamino]-2-propanol, procedimiento para su preparación y composiciones farmacéuticas que lo contienen. UY25108A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97112491A EP0893440A1 (en) 1997-07-22 1997-07-22 Thermodynamically stable modification of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole, process for its preparation and pharmaceutical compositions containing it

Publications (1)

Publication Number Publication Date
UY25108A1 true UY25108A1 (es) 2000-12-29

Family

ID=8227094

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25108A UY25108A1 (es) 1997-07-22 1998-07-22 Modificación termodinámicamente estable de 1-(4-carbazoliloxi)-3-[2-(2-metoxifenoxi)etilamino]-2-propanol, procedimiento para su preparación y composiciones farmacéuticas que lo contienen.

Country Status (32)

Country Link
EP (2) EP0893440A1 (es)
JP (1) JP2001510824A (es)
KR (1) KR100336229B1 (es)
CN (1) CN1125047C (es)
AR (1) AR015133A1 (es)
AT (1) ATE236123T1 (es)
AU (1) AU740453B2 (es)
BR (1) BR9810776A (es)
CA (1) CA2296637C (es)
CZ (1) CZ296947B6 (es)
DE (1) DE69812964T2 (es)
DK (1) DK1000027T3 (es)
ES (1) ES2195366T3 (es)
HK (1) HK1029339A1 (es)
HR (1) HRP980406A2 (es)
HU (1) HUP0003198A3 (es)
IL (1) IL133677A (es)
MA (1) MA26523A1 (es)
MY (1) MY117734A (es)
NO (1) NO313588B1 (es)
NZ (1) NZ502136A (es)
PE (1) PE96999A1 (es)
PL (1) PL191602B1 (es)
PT (1) PT1000027E (es)
RU (1) RU2202542C2 (es)
SI (1) SI1000027T1 (es)
TR (1) TR200000148T2 (es)
TW (1) TW505631B (es)
UY (1) UY25108A1 (es)
WO (1) WO1999005105A1 (es)
YU (1) YU2200A (es)
ZA (1) ZA986475B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2402336C (en) * 2000-04-03 2008-03-11 F. Hoffmann-La Roche Ag Concentrated solutions of carvedilol
EP1655285A1 (en) * 2000-06-28 2006-05-10 Teva Pharmaceutical Industries Ltd. Method for preparation of a crystalline form of carvedilol (form II)
CN1245974C (zh) * 2000-06-28 2006-03-22 特瓦制药工业有限公司 卡维地洛
AU2002326391A1 (en) * 2001-07-13 2003-01-29 Smithkline Beecham Corporation Carvedilol polymorph
WO2003024426A1 (en) 2001-09-21 2003-03-27 Egalet A/S Controlled release solid dispersions
CN1308307C (zh) * 2001-09-28 2007-04-04 弗·哈夫曼-拉罗切有限公司 假多晶型的卡维地洛
MXPA04006909A (es) 2002-01-15 2005-04-19 Teva Pharma Solidos cristalinos de carvedilol y procesos para su preparacion.
US20050148779A1 (en) * 2002-04-30 2005-07-07 Wei Chen Carvedilol monocitrate monohydrate
CA2492084A1 (en) 2002-06-27 2004-01-08 Sb Pharmco Puerto Rico Inc. Carvedilol hydobromide
CN1678305A (zh) 2002-06-27 2005-10-05 Sb药物波多黎各公司 卡维地洛磷酸盐和/或其溶剂合物和/或相应组合物和/或治疗方法
WO2004041252A1 (en) * 2002-11-08 2004-05-21 Egalet A/S Controlled release carvedilol compositions
WO2004084868A1 (en) 2003-03-26 2004-10-07 Egalet A/S Morphine controlled release system
EP1615888A1 (en) * 2003-04-21 2006-01-18 Matrix Laboratories Ltd Process for the preparation of carvedilol form-ii
SI21616A (sl) * 2003-09-02 2005-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Nove kristalne oblike karvedilola
WO2005051383A1 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol salts, corresponding compositions, methods of delivery and/or treatment
DK1838670T3 (da) * 2004-12-09 2010-03-01 Zach System Spa Fremgangsmåde til fremstilling af carvedilol og dets enantiomere
US20070043099A1 (en) * 2005-06-09 2007-02-22 Igor Lifshitz Crystalline forms of carvedilol and processes for their preparation
WO2008002683A2 (en) 2006-06-28 2008-01-03 Teva Pharmaceutical Industries Ltd. Polymorphous forms of carvedilol phosphate
US20080249317A1 (en) * 2007-04-04 2008-10-09 Apotex Inc. Novel amorphous form of carvedilol phosphate and processes for the preparation thereof
CA2687192C (en) 2007-06-04 2015-11-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3319027A1 (de) * 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten

Also Published As

Publication number Publication date
IL133677A0 (en) 2001-04-30
WO1999005105A1 (en) 1999-02-04
EP1000027B1 (en) 2003-04-02
DE69812964T2 (de) 2004-03-04
CZ296947B6 (cs) 2006-08-16
ZA986475B (en) 2000-01-21
PL338432A1 (en) 2000-11-06
CZ2000221A3 (cs) 2000-05-17
JP2001510824A (ja) 2001-08-07
DK1000027T3 (da) 2003-07-21
EP0893440A1 (en) 1999-01-27
SI1000027T1 (en) 2003-10-31
NO20000301D0 (no) 2000-01-21
CN1264366A (zh) 2000-08-23
CN1125047C (zh) 2003-10-22
MY117734A (en) 2004-07-31
IL133677A (en) 2004-06-01
HUP0003198A3 (en) 2002-10-28
ES2195366T3 (es) 2003-12-01
PL191602B1 (pl) 2006-06-30
PE96999A1 (es) 1999-10-12
PT1000027E (pt) 2003-07-31
NO313588B1 (no) 2002-10-28
NZ502136A (en) 2002-05-31
ATE236123T1 (de) 2003-04-15
DE69812964D1 (de) 2003-05-08
AU740453B2 (en) 2001-11-01
CA2296637C (en) 2005-11-15
MA26523A1 (fr) 2004-12-20
CA2296637A1 (en) 1999-02-04
AU8631998A (en) 1999-02-16
YU2200A (sh) 2002-03-18
KR20010022097A (ko) 2001-03-15
KR100336229B1 (ko) 2002-05-09
TW505631B (en) 2002-10-11
BR9810776A (pt) 2000-09-19
EP1000027A1 (en) 2000-05-17
HUP0003198A2 (en) 2001-03-28
TR200000148T2 (tr) 2000-07-21
AR015133A1 (es) 2001-04-18
HK1029339A1 (en) 2001-03-30
NO20000301L (no) 2000-01-21
RU2202542C2 (ru) 2003-04-20
HRP980406A2 (en) 1999-04-30

Similar Documents

Publication Publication Date Title
UY25108A1 (es) Modificación termodinámicamente estable de 1-(4-carbazoliloxi)-3-[2-(2-metoxifenoxi)etilamino]-2-propanol, procedimiento para su preparación y composiciones farmacéuticas que lo contienen.
CO4750836A1 (es) Nuevos medicamentos y utilizacion (1-metiletil)-8-azoniabiciclo-[3.2.1]octnao y su uso en pre- paraciones medicas
CO5570109A1 (es) Compuestos de dihidropirimidina heterociclicos
UY26977A1 (es) Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgésicos
PT907639E (pt) Compostos polimorficos
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
NO952310L (no) Anvendelse av karbamazepin og okskarbazepin ved behandling av Parkinsons sykdom og Parkinsonianske syndromer
PA8467401A1 (es) Procedimiento para tratar la insuficiencia cardiaca
PA8426801A1 (es) Composiciones farmaceuticas para el tratamiento de la rinitis.
UY27461A1 (es) Formas pseudopolimorficas de cardevilol.
CA2216664A1 (fr) Nouvelles amines cycliques n-substituees, leur procede de preparation et les compositions pharmaceutiques les renfermant
PE20001325A1 (es) Combinacion de cerivastatina y fibratos
CO4940448A1 (es) Modificacion a cristal de una sustancia de medicamento
PE20021016A1 (es) Conjugados de pregabalina-lactosa
AR006281A1 (es) Utilizacion de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4- piperidinometanol o sus sales de adicion de acidos farmaceuticamenteaceptables en el tratamineto de trastornos depresivos y trastornos bipolares
ES2158094T3 (es) Sales de adicion de acido de compuestos de 2,3,4,5-tetrahidro-1h-3-benzazepina.
AR037496A1 (es) Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables
AR014082A1 (es) Concentrado oral de sertralina
UY27920A1 (es) Combinaciones de epinastina, pseudoefedrina y metilefedrina como nuevas formulaciones farmaceuticas
BR0208814A (pt) Uso de derivados de ariletenossulfonamida
ECSP982599A (es) Modificacion termodinamicamente estable de 1-(4-carbazoliloxi)-3-[2-(2-metoxifenoxi) etilamino]-2-propanol, proceso para su preparacion y composicion farmaceutica que lo contiene
AR003949A1 (es) La sal fumarato de (r)-5-(metilaminosulfonil-metil)-3-(n-metilpirrolidin-2- ilmetil)-1h-indol, su uso, un procedimiento para prepararlo y una composicionfarmaceutica que la comprende.
DK0678022T3 (da) Anvendelse af riluzol ved fremstilling af lægemidler, som er anvendelige til behandling af stråleskader
UY27960A1 (es) S-(+)-3-(1-(2-(2,3-dihidro -1h-indol-3-il)etil)3,6-dihidro-2h-piridin-4-il)-6-cloro-1h-indol y slaes de adición de ácido del mismo.
AR001687A1 (es) Producto farmacéutico apropiado para el tratamiento parenteral de daños producidos por enfermedades isquemicas focales permanentes que comprende (s)-adenosil-l-metionina (SAMe)

Legal Events

Date Code Title Description
VENC Patent expired

Effective date: 20180722